通过表达靶向 APC 抗原的 mRNA 疫苗预防和治疗 HPV 相关癌症

Persistent human papillomavirus (HPV) infection is associated with multiple malignancies. Developing therapeutic vaccines to eliminate HPV-infected and malignant cells holds significant value. In this study, we introduced a lipid nanoparticle encapsulated mRNA vaccine expressing tHA-mE7-mE6. Mutations were introduced into E6 and E7 of HPV to eliminate their tumourigenicity. A truncated influenza haemagglutinin protein (tHA), which binds to the CD209 receptor on the surface of dendritic cells (DCs), was fused with mE7-mE6 in order to allow efficient uptake of antigen by antigen presenting cells.

The tHA-mE7-mE6 (mRNA) showed higher therapeutic efficacy than mE7-mE6 (mRNA) in an E6 and E7 + tumour model. The treatment resulted in complete tumour regression and prevented tumour formation. Strong CD8 + T-cell immune response was induced, contributing to preventing and curing of E6 and E7 + tumour. Antigen-specific CD8 + T were found in spleens, peripheral blood and in tumours.

In addition, the tumour infiltration of DC and NK cells were increased post therapy.

In conclusion, this study described a therapeutic mRNA vaccine inducing strong anti-tumour immunity in peripheral and in tumour microenvironment, holding promising potential to treat HPV-induced cancer and to prevent cancer recurrence.